About us

A history of spray drying and CDMO support

Why work with us

Upperton is a specialist pharmaceutical CDMO that can, within days of initial contact, start feasibility studies with only a few milligrams of a client’s drug candidate. We offer our clients a complete development package, across all dry powder dosage forms: powders, capsules, tablets, devices for nasal and pulmonary delivery.  With experience of working on a range of dosage forms and the expertise to develop the most challenging molecules. From the beginning, our clients will talk to an expert scientific team, who will manage projects with a science-led approach.

What we do

Upperton Pharma Solutions is a specialist CDMO providing formulation and dosage form development services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing.

We are able to enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular we are one of the world leaders on expertise and know-how in pharmaceutical spray dryings; probably the most versatile and fastest growing technology in the industry.

We have experience of working with a range of dosage forms and the expertise to develop the most challenging of molecules. Our formulation work is complemented by a comprehensive range of analytical services for product testing and ICH stability studies.

Upperton has an extensive, multinational client-base, ranging from virtual and small start-ups to global pharma companies. We pride ourselves on our client-focused, flexible approach and scientific excellence.

History

Upperton Limited was founded in 1999 by Dr Richard Johnson. The company began life as a spray drying consultation service. In 2008, Upperton started working with external clients on various small spray drying projects; laying the foundation for Upperton’s R&D department.

The R&D department continued to grow organically, through company reinvestment. The team has now completed over 300 projects, several of which have now been launched as commercial products with many others in advanced stages of clinical development.

In November 2018, Upperton completed a successful MHRA inspection and subsequent grant of our MHRA license. This license allows us to manufacture IMP bulk powder and a range of dry powder dosage forms; supporting clinical trials up to Phase III. This marked a turning point in the company’s history, with transition from a CRO to a CDMO. A science-led approach remains at the heart of our R&D activities, whilst our clinical trial manufacturing capabilities enables us to support our clients all the way into the clinic.

Management Team

Richard Johnson
Founder & CEO

Dr Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Richard previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix). Richard holds an honours degree in Biology from University of York and a Ph.D. from the University of Warwick and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.

Ian Lafferty
Technical Director

Dr Ian Lafferty has recently joined Upperton Pharma Solutions as a Technical Consultant. Ian has 25 years’ technical and operational experience in early phase pharmaceutical development encompassing the formulation design, development, process optimisation and manufacture of a wide range of dosage forms including oral solids, inhaled powders, suspensions and injectables with a focus on challenging molecules, enabling technologies and high potent handling. He also has significant experience in facility design and management.

Ian has held senior roles at several emerging and growing CDMOs providing strategic and operational leadership to ensure excellence in all aspects of providing pharmaceutical services.

Paul Kelsall
Director of Clinical Manufacturing

Paul Kelsall joined Upperton Pharma Solutions in August 2018. Paul has over 20 years of experience in the pharmaceutical industry, having previously worked for Boots, Reckitt Benckiser, Nova Laboratories and Aesica. Paul’s experience covers both Sterile and Non-Sterile Manufacturing, Formulation Development, Facilities Management and Business Improvement. Paul’s responsibilities include managing the Upperton Pharma Solutions Facility and all the GMP Operations that are conducted on site. Paul is also responsible for the New Business Introduction of all GMP projects.

Sarah Bayliss
Director of Quality & Compliance

Sarah Bayliss joined Upperton in December 2017 as Director of Quality and Compliance. Her previous roles include Corporate QA Operations Manager, Head of Quality, Technical Manager and General Manager for pharmaceutical and medical device businesses within the manufacturing areas of Europe and the USA. Sarah has over 20 years’ experience of implementing, maintaining and remediating Quality Management Systems, working under MIA, IMP, MS and WD licences. Sarah is responsible for ensuring that Upperton Pharma Solutions are compliant and that our Quality Management Systems are implemented and adhered to in-line with the site relevant licensing activities (GMP) under MHRA & FDA regulations.

Karen Coombes
Commercial Director

Karen Coombes joined Upperton Pharma Solutions as Operations Director in 2008, having previously held positions at Advanced Protein Systems, Andaris Limited (Vectura) and Unilever Research. Karen holds an honours degree in Chemistry from the University of Bath and a master’s degree in Biotechnology from the University Of Nottingham and has a wealth of experience in the pharmaceutical and biotechnology industry. Karen is responsible for scale up projects and for directing all non GMP manufacturing activities in the company’s pilot plant.

Laura Mason
Director of Business Operations

Dr Laura Mason joined Upperton in 2016 as a Project Scientist, quickly progressing to the role of Business Operations Director. Laura has previous experience within solid oral dosage form development having completed her PhD in the School of Pharmacy at the University of Nottingham, and her Pharmacy Pre-Registration Year at Merck Sharp and Dohme and Guy’s & St Thomas’ Hospital. Laura is a UK Registered Pharmacist, the current treasurer of the UKICRS and a member of several pharmaceutical societies. Laura supports the introduction and co-ordination of the company’s R&D projects.

Can we help you?